Accutane and pregnancy [12] (multiple letters)

Journal of the American Academy of Dermatology

Volumn 49, Issue 6, 2003, Pages 1201-1202

  Mitchell, Allen A ^a   Van Bennekom, Carla M ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; DERMATOLOGICAL AGENT;

DRUG EXPOSURE; DRUG FORMULATION; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; LETTER; OUTPATIENT; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; SAMPLE SIZE; DRUG EFFECT; FEMALE; NOTE; UNWANTED PREGNANCY;

DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; PREGNANCY; PREGNANCY, UNWANTED;

EID: 0642334353     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)02162-5     Document Type: Letter

References (4)

1. Mitchell AA, Van Bennekom CM, Louik C. An assessment of the Accutane (isotretinoin) Pregnancy Prevention Program. FDA Dermatologic Drugs Advisory Committee Meeting; 2000 September 18; Gaithersburg (MD). Available from: www.fda.gov/ohrms/dockets/ac/00/backgrd/3639b1c_03.pdf.
2. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001;45:196-207.
3. Brinker A, Trontell A, Beitz J. Pregnancy and pregnancy rates in association with isotretinoin (Accutane). J Am Acad Dermatol 2002;47:798-9.
4. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995;333:101-6.